HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Henriquez, F. Articles by Roberts, F. Search for Related Content PubMed PubMed Citation Articles by Henriquez, F. Articles by Roberts, F.

The T1799A BRAF Mutation Is Present in Iris Melanoma

¹From the School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom; the ²Division of Infection and Immunity, FBLS, University of Glasgow, Glasgow, Scotland, United Kingdom; the ³Tennent Institute of Ophthalmology, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom; and the ⁴Department of Pathology, Western Infirmary, Glasgow, Scotland, United Kingdom.

PURPOSE. An activating mutation in exon 15 of the BRAF gene has been found in a high proportion of cutaneous pigmented lesions, but only in one case of uveal melanoma. Iris melanoma is the least common uveal melanoma and displays a less aggressive clinical course compared with posterior uveal melanoma. To date, no study has been conducted to investigate the T1799A mutation in iris melanoma. The purpose of this study was to determine whether the T1799A BRAF mutation is present in iris melanoma.

METHODS. DNA was extracted from 19 archival, paraffin-embedded tissue sections of iris melanomas. Nested PCR was used to amplify exon 15 of the BRAF gene, and the product was purified, cloned into a sequencing vector, and sequenced. The sequences obtained were compared with the wild-type sequence of the BRAF gene. The presence or absence of the BRAF mutation was also compared with the clinicopathological features.

RESULTS. The T1799A mutation was identified by sequencing in 9 of 19 iris melanomas. Six of the 9 cases with the BRAF mutation were recurrent tumors. All other tumors were resections for primary tumors. There was a statistically significant association between the BRAF mutation and recurrent tumor (P = 0.003). There was no association between the presence of the BRAF mutation and other clinicopathological characteristics.

CONCLUSIONS. In this small study, the T1799A BRAF mutation was identified in almost half of the iris melanoma tissues samples examined. This finding suggests that there may be genetic as well as clinical differences between iris and posterior uveal melanomas.

This article has been cited by other articles:

				M. D. Onken, L. A. Worley, M. D. Long, S. Duan, M. L. Council, A. M. Bowcock, and J. W. Harbour Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., December 1, 2008; 49(12): 5230 - 5234. [Abstract] [Full Text] [PDF]

				R. Folberg, S. S. Kadkol, S. Frenkel, K. Valyi-Nagy, M. J. Jager, J. Pe'er, and A. J. Maniotis Authenticating Cell Lines in Ophthalmic Research Laboratories Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4697 - 4701. [Full Text] [PDF]